Cannabis Science, Inc., a US Company specializing in cannabis formulation-based drug development, has signed a broad licensing agreement with strategic partner Endocan Corporation to use patent N2010968, entitled "Composition for the Treatment of Neurobehavioral Disorders", for Endocan studies, research and development, and consumer products.

As previously announced, the subject of the patent is development of cannabinoid-based formulations to treat a variety of widespread neurobehavioral conditions, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders. The products that Endocan intends to produce using the patent will target substantial international markets that should prove to help many people in need worldwide. At the same time, Cannabis Science will be moving forward with research and clinical development of pharmaceutical grade drugs via the patent.

"We are very excited with the quick movement in reaching a mutually-beneficial agreement with Endocan Corporation regarding the use of our recently filed patent addressing cannabinoid-based treatment for various neurobehavioral disorders. Both of these companies have different but synergistic missions and can together take this intellectual property to the market at multiple levels," stated Dr Dorothy Bray, CEO and director, Cannabis Science, Inc.

Cannabis Science's IP strategy includes developing, owning, and licensing patents for the Company's proprietary drug development operations and collaborations with other industry actors to most effectively help patients.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.